Recombinant Activated Factor VII in Patients at High Risk of Bleeding

References

• Hedner, U., Glazer, S., Pingel, K., Alberts, K.A., Blomback, M., Schulman, S. and Johnsson, H. (1988) "Successful use of recombinant factor Vila in patient with severe haemophilia A during synovectomy", Lancet 2, 1193.
   PubMed Web of Science ®Google Scholar
• Abshire, T. and Kenet, G. (2004) "Recombinant factor Vila: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VBI or IX inhibitors", J. Thromb. Haemost. 2, 899–909.
   PubMed Web of Science ®Google Scholar
• Shapiro, A.D., Gilchrist, G.S., Hoots, W.K., Cooper, H.A. and Gastineau, D.A. (1998) "Prospective, randomised trial of two doses of rFVIIa (NovoSeven®) in haemophilia patients with inhibitors undergoing surgery", Thromb. Haemost. 80, 773–778.
   PubMed Web of Science ®Google Scholar
• Levi, M., Bijsterveld, N.R. and Keller, T.T. (2004) "Recom-binant factor VIIa as an antidote for anticoagulant treatment", Semin. Hematol. 41\(Suppl. 1), 65–69.
   PubMed Web of Science ®Google Scholar
• Berntorp, E. (2000) "Recombinant FVIIa in the treatment of warfarin bleeding", Semin. Thromb. Haemost. 26, 433–435.
   PubMed Web of Science ®Google Scholar
• Lewis, B., O'Leary, M. and Vinh, T. (2001) "Successful use of rVIIa (NovoSeven®) to reverse enoxaparin (levonox) over-dose in an adult patient with intracranial bleeding", Thromb. Haemost. 84, P2633, ( Abstr.).
   Google Scholar
• Silva, M.A., Nuralidharan, V. and Mirza, D.F. (2004) "The management of coagulopathy and blood loss in liver surgery", Semin. Hematol. 41\(Suppl. 1), 132–139.
   PubMed Web of Science ®Google Scholar
• Kositchaiwat, C. and Chuansumrit, A. (2001) "Experiences with recombinant factor Villa for the prevention of bleeding in patients with chronic liver disease undergoing percuta-neous liver biopsies and endoscopic retrograde cholangio-pancreatography (ERCP)", Thromb. Haemost. 86, 1125–1126.
   PubMed Web of Science ®Google Scholar
• Jeffers, L., Bernstein, D.E. and Erhardtsen, E. (1998) "The use of recombinant factor Vila in laparoscopy liver biopsy: a pilot trial", Gastroenterology 114, L0275.
   PubMed Web of Science ®Google Scholar
• Bernstein, D.E., Jeffers, L., Erhardtsen, E., Reddy, K.R., Glazer, S., Squiban, P., Bech, R., Hedner, U. and Schiff, E.R. (1997) "Recombinant factor Villa corrects prothrombin time in cirrhotic patients: a preliminary study", Gastroenterology 113, 1930–1937.
   PubMed Web of Science ®Google Scholar
• Fressinaud, E., Sigaud-Fiks, M., Le Boterff, C. and Piot, B. (1998) "Use of recombinant factor Villa (Novo Seven®) for dental extraction in patient affected by platelet-type (pseudo-) von Willebrand disease", Haemophilia 4, 299 (Abstr.).
   Google Scholar
• Goodnough, L.T. (2004) "Experiences with recombinant human factor Vila in patients with thrombocytopenia", Semin. Hematol. 41 (Suppl. 1), 25–29.
   PubMed Web of Science ®Google Scholar
• Kristensen, J., Killander, A., Hippe, E., Helleberg, C., Ellegard, J., Holm, M., Kutti, J., Mellqvist, U.H., Johansson, J.E., Glazer, S. and Hedner, U. (1996) "Clinical experience with recombinant factor Vila in patients with thrombocytopenia", Haemostasis 26, 159–164.
   PubMedGoogle Scholar
• Gerotziafas, G.T., Zervas, C., Gavrielidis, G., Tokmaktsis, A., Hatjiharissi, E., Papaioannou, M., Lazaridou, A., Constantinou, N., Samama, M.M. and Christakis, J. (2002) "Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage", Am. J. Hematol. 69, 219–222.
   PubMed Web of Science ®Google Scholar
• Osborne, W., Bhandari, S., Tait, R.C. and Franklin, I.M. (2004) "Immediate haemostasis with recombinant factor VIIa for haemorrhage following Hickman line insertion in acute myeloid leukaemia", Clin. Lab. Haematol. 26, 229–231.
   PubMedGoogle Scholar
• Poon, M.C., D'Oiron, R., Von Depka, M., Khair, K., Negrier, C., Karafoulidou, A., Huth-Kuehne, A. Morfini, M. and International Data Collection on Recombinant Factor VIIa and Congenital Platelet Disorders Study Group (2004) "Prophylactic and therapeutic recombinant factor VIIa administration to patient with Glanzmann's thrombas-thenia: results of an international survey", J. Thromb. Haemost. 2, 1096–1103.
   PubMed Web of Science ®Google Scholar
• Poon, M.C., Demers, C., Jobin, F. and Wu, J.W. (1999) "Recombinant factor Vila is effective for bleeding and surgery in patients with Glanzmann thrombasthenia", Blood 94, 3951–3953.
   PubMed Web of Science ®Google Scholar
• Peters, M. and Heijboer, H. (1998) "Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor Vila", Thromb. Haemost. 80, 352.
   PubMed Web of Science ®Google Scholar
• Revesz, T., Arets, B., Bierings, M., van den Bos, C. and Duval, E. (1998) "Recombinant factor VIIa in severe uremic bleeding (letter)", Thromb. Haemost. 80, 353.
   PubMed Web of Science ®Google Scholar
• Monroe, D.M., Hoffman, M., Allen, G.A. and Roberts, H.R. (2000) "The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia", Semin. Thromb. Haemost. 26, 373–377.
   PubMed Web of Science ®Google Scholar
• Stepinska, J., Banaszewski, M., Konopka, A. and Szajewski, T. (2002) "Activated recombinant factor VII (rFVIIa) in bleeding managment after therapy with IIb/IIIa-inhibitor tirofiban", Thromb. Haemost. 87,355–356.
   PubMed Web of Science ®Google Scholar
• Mariani, G., Testa, M.G., Di Paolantonio, T., Molskov, B.R. and Hedner, U. (1999) "Use of recombinant activated factor VII in the treatment of congenital factor VII deficiences", Vox Sang. 77, 131–136.
   PubMed Web of Science ®Google Scholar
• Mathijssen, N.C., Masereeuw, R., Verbeek, K., Lavergne, J.M., Costa, J.M., Van Heerde, W.L. and Novakova, I.R. (2004) "Prophylactic effect of recombinant factor VIIa in factor VII deficient patients", Br. J. Haematol. 125, 494–499.
   PubMed Web of Science ®Google Scholar
• Hendriks, H.G., Meijer, K., de Wolf, J.T.M., Klompmaker, I.J., Porte, R.J., de Kam, P.J., Hagenaars, A.J.M., Melsen, T., Slooff, M.J.H. and Van der Meer, J. (2001) "Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study", Transplan-tation 71, 402–405.
   PubMed Web of Science ®Google Scholar
• Bosch, J. and Abraldes, J.G. (2004) "Management of gastrointestinal bleeding in patients with cirrhosis of the liver", Semin. Hematol. 41\(Suppl. 1), 8–12.
   PubMed Web of Science ®Google Scholar
• Thabur, D., de Franchis, R., Bendtsen, F. and Cooperative Study Group (2003) "Efficacy of activated recombinant factor VIIa (rFVIIa; NovoSeven®) in cirrhotic patients with upper gastrointestinal bleeding: A randomised placebo-controlled double-blind multicenter trial", J. Hepatol. 38(Suppl.), 13A.
   Google Scholar
• D'Amico, G., De Franchis, R. and Cooperative Study Group (2003) "Upper digestive bleeding in cirrhosis. Post-thera-peutic outcome and prognostic indicators", Hepatology 38, 599–612.
   PubMed Web of Science ®Google Scholar
• Kenet, G., Walden, R., Eldad, A. and Martinowitz, U. (1999) "Treatment of traumatic bleeding with recombinant factor Vila", Lancet 354, 1879.
   PubMed Web of Science ®Google Scholar
• Martinowitz, U., Kenet, G., Segal, E., Luboshitz, J., Lubetsky, A., Ingerslev, J. and Lynn, M. (2001) "Recombinant activated factor VII for adjunctive hemorrhage control in trauma", J. Trauma 51, 431–439.
   PubMed Web of Science ®Google Scholar
• Lynn, M., Jeroukhimov, I., Jewelewicz, D., Popkin, C., Johnson, E.W., Rashid, Q.N., Brown, M., Martinowitz, U. and Cohn, S.M. (2002) "Early use of recombinant factor VIIa improves mean arterial pressure and may potentially decrease mortality in experimental hemorrhagic shock: a pilot study", J. Trauma 52, 703–707.
   PubMed Web of Science ®Google Scholar
• Pihusch, M. (2004) "Bleeding complications after hemato-poietic stem cell transplantation", Semin. Hematol. 41 (Suppl. 1), 93–100.
   PubMed Web of Science ®Google Scholar
• Blatt, J., Gold, S.H., Wiley, J.M., Monahan, P.E., Cooper, H.C. and Harvey, D. (2001) "Of-label use of recombinant factor VIIa in patients following bone marrow transplantation", Bone Marrow Transplant. 28, 405–407.
   PubMed Web of Science ®Google Scholar
• Aldouri, M., Shafi, T., Al Khudairi, D., Al Bokhari, E., Black, L., Akinwale, N., Osman Musa, M., Al Homaidhi, A., Al Fagih, M.B. and Andreasen, R. (2000) "Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven®) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery", Blood Coagul. Fibrinolysis 11\(Suppl. 1), S121—S127.
   PubMedGoogle Scholar
• Bouwmeester, F.W., Jonkhoff, A.R., Verheijen, R.H.M. and Van Geijn, H.P. (2003) "Successful treatment of life-threatening postpartum hemorrhage with recombinant activated factor VII", Obstet. Gynecol. 101, 1174–1176.
   PubMed Web of Science ®Google Scholar
• Holcomb, J.B., Neville, H.L., Fischer, C.F. and Hoots, K. (2003) "Use of recombinant FVIIa for intraperitoneal coagulopathic bleeding in a septic patient", Curr. Surg. 60, 423–427.
   PubMedGoogle Scholar
• Friederich, P.W., Geerdink, M.G., Spataro, M., Messelink, E.J., Henny, C.P., Buller, H.R. and Levi, M. (2000) "The effect of the administration of recombinant activated factor VII (NovoSeveng), on perioperative blood loss in patients undergoing transabdominal retropubic prostatectomy: the PROSE study", Blood Coagul. Fibrinoylsis 11\(Suppl. 1), S129—S132.
   PubMedGoogle Scholar
• Hedner, U. and Erhardtsen, E. (2002) "Potential role for rFVIIa in transfusion medicine", Transfusion 42, 114–124.
   PubMed Web of Science ®Google Scholar
• Wildgoose, P., Nemerson, Y, Hansen, L.L., Nielsen, F.E., Glazer, S. and Hedner, U. (1992) "Measurement of basal levels of factor VIIa in hemophilia A and B patients", Blood 80, 25–28.
   PubMed Web of Science ®Google Scholar
• Roberts, H.R., Monroe, D.M., Oliver, J.A., Chang, J.Y. and Hoffman, M. (1998) "Newer concepts of blood coagulation", Haemophilia 4, 331–334.
   PubMed Web of Science ®Google Scholar
• Hedner, U. and Kiesel, W. (1983) "Use of human factor VIIa in the treatment of two haemophilia A patients with high-titer inhbitors", J. Clin. Investig. 71, 1836–1841.
   PubMed Web of Science ®Google Scholar
• Berkner, K., Busby, S., Davie, E., Hart, C., Insley, M., Kisiel, W., Kumar, A., Murray, M., O'Hara, P. and Woodbury, R. (1986) "Isolation and expression of cDNA encoding human factor VII", Quant. Biol. 51, 531–541.
   PubMedGoogle Scholar
• Heuer, L. and Blumenberg, D. (2002) "Recombinant factor VIIa (NovoSeven®) A review of current and possible future indications", Anaesthesist 51, 388–399.
   PubMed Web of Science ®Google Scholar
• Hoffman, M., Monroe, D.M. and Roberts, H.R. (1998) "Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII", Blood Coagul. Fibrinolysis 9\(Suppl. 1), 561—S65.
   Google Scholar
• Monroe, D.M., Hoffman, M., Oliver, J.A. and Roberts, H.R. (1997) "Platelet activity of high-dose factor VIIa is independent of tissue factor", Br. J. Haematol. 99, 542–547.
   PubMed Web of Science ®Google Scholar
• Hoffman, M. and Monroe, D.M. (2001) "A cell-based model of hemostasis", Thromb. Haemost. 85, 958–965.
   PubMed Web of Science ®Google Scholar
• Hedner, U. (2004) "Background rationale for current clinical trials on NovoSeven® within haemophilia", Haematologica 89\(Suppl. 1), 13–15.
   Google Scholar
• Monroe, D.M., Hoffman, M. and Roberts, H.R. (2002) "Platelets and thrombin generation", Art. Thromb. Vasc. Biol. 22, 1381–1389.
   PubMed Web of Science ®Google Scholar
• He, S., Blombäck, M., Jacobsson Ekman, G. and Hedner, U. (2003) "The role of recombinant factor VIIa (rVIIa) in fibrin structure in the absence of FVBI/FIX", J. Thromb. Haemost. 1, 1215–1219.
   PubMed Web of Science ®Google Scholar
• Lisman, T., Mosnier, L.O., Lambert, T., Mauser-Bunschoten, E.P., Meijers, J.C.M., Nieuwenhuis, H.K. and de Groot, P.G. (2002) "Inhibition of fibrinolysis by recombinant factor Villa in plasma from patients with severe hemophilia A", Blood 99, 172–179.
   Web of Science ®Google Scholar
• Doughty, H.A., Northeast, A., Sklair, L., Rogues, T., Young, A.E., Savidge, G.F. and Hunt, B.J. (1995) "The use of recombinant factor VIIa in a patient with acquired haemophilia A undergoing surgery", Blood Coagul. Fibrinolysis 6, 125–128.
   PubMed Web of Science ®Google Scholar
• Hedner, U. (1999) "Treatment of patients with factor VBI and factor IX inhibitors with special focus on the use of recombinant factor Vita", Thromb. Haemost. 82, 531–539.
   PubMed Web of Science ®Google Scholar
• Johannessen, M., Andreasen, R.B. and Nordfang, O. (2000) "Decline of factor VBI and factor IX inhibitors during long-term treatment with NovoSeveng", Blood Coagul. Fibrinolysis 11, 239–242.
   PubMed Web of Science ®Google Scholar
• Hedner, U. (2003) "Recombinant factor VlIa (NovoSeven®) as a hemostatic agent", Dis. Mon. 49, 39–48.
   PubMed Web of Science ®Google Scholar
• Kjalke, M., Ezban, M., Monroe, D.M., Hoffman, M., Roberts, H.R. and Hedner, U. (2001) "High dose factor VlIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system", Br. J. Haematol. 114, 114–120.
   PubMed Web of Science ®Google Scholar
• Parameswaran, R., Shapiro, A.D., Gill, J.C. and Kessler, C.M. for the HRS registry investigators (2002) "Dose effect and efficacy of recombinant factor VlIa (FVlIa) in the treatment of hemophilia patients with inhibitors: analysis from the hemophilia research society (HRS) registry", Blood 100, 97a.
   Web of Science ®Google Scholar
• Cooper, H.A., Jones, C.P., Campion, E., Roberts, H.R. and Hedner, U. (2001) "Rationale for the use of high dose rFVlIa in a high titre inhibitor patient with haemophilia B during major orthopaedic procedures", Haemophilia 7, 517–522.
   PubMed Web of Science ®Google Scholar
• Abshire, T.C. (2004) "Dose optimization of recombinant factor VlIa for control of mild to moderate bleeds in inhibitor patients: improved efficacy with higher dosing", Semin. Hematol. 41\(Suppl. 1), 3–7.
   PubMed Web of Science ®Google Scholar
• Schulman, S., Bech Jensen, M. and Varon, D. (1996) "Feasibility of using recombinant factor VlIa in continuous infusion", Thromb. Haemost. 75, 432.
   PubMed Web of Science ®Google Scholar
• Hanovd, M., Galajda, P. and Kubisz, P. (1998) "Successful treatment of hemothorax using rEVlIa", Haemophilia 4, 242 (Abstr.).
   Google Scholar
• Collins, P.W. (2004) "Acquired haemophilia A: immune suppression", Haematologica 89\(Suppl. 5), 3–7.
   Google Scholar
• Hay, C.R.M. (1998) "Acquired haemophilia", Ballieres Clin. Haematol. 11, 287–303.
   PubMed Web of Science ®Google Scholar
• Cohen, A.J. and Kessler, C.M. (1996) "Acquired inhibitors", Ballieres Clin. Haematol. 9, 331–354.
   PubMed Web of Science ®Google Scholar
• Von Depka, M. (2002) "NovoSeven: mode of action and use in acquired haemophilia", Intensive Care Med. 28, S222—S227.
   PubMed Web of Science ®Google Scholar
• Hay, C.R.M., Negrier, C. and Ludlam, C.A. (1997) "The treatment of bleeding in acquired haemophilia A with recombinant factor Vila: a multicenter study", Thromb. Haemost. 78, 1463–1467.
   PubMed Web of Science ®Google Scholar
• Arkin, S., Blei, E, Foulke, R., Gilchrist, G.S., Heisel, M.A., Key, N., Kisker, C.T., Kitchen, C., Shafer, F.E., Shah, P.C. and Strickland, D. (2000) "Human coagulation factor FVlIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from NovoSeven® emergency-use programme in patients with severe haemophilia or with acquired inhibitors", Blood Coagul. Fibrinolysis 11, 255–259.
   PubMed Web of Science ®Google Scholar
• Green, D. and Lechner, K. (1981) "A survey of 215 non-hemophilic patients with inhibitors to factor VBI", Thromb. Haemost. 45, 200–203.
   PubMed Web of Science ®Google Scholar
• Hunovi, M. and Kubisz, P. (2002) "The clinical use of rEVlIa-our analysis", Haemophilia 8, 555 (Abstr.).
   Google Scholar
• Mariani, G. and Dolce, A. (2004) "Congenital factor VII deficiency: clinical picture and management", Haematologica 89\(Suppl. 5), 18–21.
   Google Scholar
• Van Heerde, W.L. (2004) "Prophylactic use of rEVII in congenital factor VII deficiency: mechanism of action", Haematologica 89\(Suppl. 5), 22–24.
   Google Scholar
• Kubisz, P., Plameriovi, I., Chudej, J., Stagko, J. and Hulikovd, M. (2003) "Recombinant activated factor Vila in patients at the high risk of bleeding", Blood 102, 103b, (Abstr.).
   Web of Science ®Google Scholar
• George, J.N., Caen, J.P. and Nurden, A.T. (1990) "Glanzmann's thrombasthenia: the spectrum of clinical disease", Blood 75, 1383–1395.
   PubMed Web of Science ®Google Scholar
• Martin, I., Kriaa, E, Proulle, V, Guillet, B., Kaplan, C., D'Oiron, R., Debre, M., Fressinaud, E., Laurian, Y, Tchernia, G., Charpentier, B., Lambert, T. and Dreyfus, M. (2002) "Protein A Sepharose immunoadsorption can restore the efficacy of platelet concentrates in patients with Glanzmann's thrombasthenia", Br. J. Haematol. 119,991–997.
   PubMed Web of Science ®Google Scholar
• Tengborn, L. and Petruson, B. (1996) "A patient with Glanzmann's thrombasthenia and epistaxis successfuly treated with recombinant factor Vita", Thromb. Haemost. 75, 981–982.
   PubMed Web of Science ®Google Scholar
• Lollike, K. (2004) "Current Novo Nordisk sponsored clinical trials on NovoSeven® outside haemophilia", Haematologica 89\(Suppl. 5), 16–17.
   Google Scholar
• van Es, R.F., Jonker, J.J., VerheRgt, F.W., Deckers, J.W. and Grobbee, D.E. (2002) "Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial", Lancet 360, 109–113.
   PubMed Web of Science ®Google Scholar
• Crowther, M.A., Julian, J., McCarty, D., Douketis Kovacs, M., Biagoni, L., Schnurr, T., McGinnis, J., Gent, M., Hirsh, J. and Ginsberg, J. (2000) "Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial", Lancet 356, 1551–1557.
   PubMed Web of Science ®Google Scholar
• Erhardtsen, E., Nony, P., Dechavanne, M., Ffrench, P., Boissel, J.P. and Hedner, U. (1998) "The effect of recombinant factor VlIa (NovoSeven®) in healthy volunteers receiving acenocoumarol to an international normalized ratio above 2.0", Blood Coagul. Fibrinolysis 9, 741–748.
   PubMed Web of Science ®Google Scholar
• Deveras, R.A. and Kessler, C.M. (2002) "Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VlIa concentrate", Ann. Intern. Med. 137, 884–888.
   PubMed Web of Science ®Google Scholar
• Sorensen, B., Johansen, P., Nielsen, G.L., Sorensen, J.C. and Ingerslev, J. (2003) "Reversal of the International Normal-ized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophyl-axis: Clinical and biochemical aspects", Blood Coagul. Fibrinolysis 14, 469–477.
   PubMed Web of Science ®Google Scholar
• Heuer, L., Denter, M., Rehra, N. and Blumenberg, D. (2002) "Recombinant factor VlIa (rEVlIa) stops severe bleeding from abdominal wall haematoma induced by an overdose of heparin in a high risk patient-case report", Br. J. Anaesth. 89\(Suppl. 5), 19–20, (Abstr.).
   Google Scholar
• Wolzt, M., Levi, M., Sarich, T.C., Bostrom, S.L., Ericsson, U.G., Ericsson-Lepkowska, M., Svensson, M., Weitz, J.I., Elg, M. and Wahlander, K. (2004) "Effect of recombinant factor VlIa on melagatran-induced inhibition of thrombin genera-tion and platelet activation in healthy volunteers", Thromb. Haemost. 91, 1090–1096.
   PubMed Web of Science ®Google Scholar
• Bijsterveld, N.R., Moons, A.H., Boekholdt, S.M., Van Aken, BE., Fennema, H., Peters, R.J., Meijers, J.C. and Buller, H.R. (2002) "Ability of recombinant factor FVlIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers", Circulation 106, 2550–2554.
   PubMed Web of Science ®Google Scholar
• Bijsterveld, N.R., Vink, R., Van Aken, BE., Fennema, H., Peter, R.J., Meijers, J.C., Buller, H.R. and Levi, M. (2004) "Recombinant factor VlIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers", Br. J. Haematol. 124, 653–658.
   PubMed Web of Science ®Google Scholar
• Hedner, U., Berqvist, D., Ljungberg, J. and Nilson, B. (1985) "Haemostatic effect of factor VlIa in thrombocytopenic rabbits", Blood 66\(Suppl. 1), 132.
   Google Scholar
• Vidarsson, B. and Onundarson, ET. (2000) "Recombinant factor VlIa for bleeding in refractory thrombocytopenia", Thromb. Haemost. 83, 634–635.
   PubMed Web of Science ®Google Scholar
• Erhardtsen, E. (2002) "Ongoing NovoSeven® trials", Intensive Care Med. 28\(Suppl. 2), S248—S255.
   PubMedGoogle Scholar
• Meijer, K., Sieders, E., Slooff, M.J.H., de Wolf, J.T.H. and Van der Meer, J. (1998) "Effective treatment of severe bleeding due to acquired thrombocytopathia by single dose admin-istration of activated recombinant factor VII", Thromb. Haemost. 80, 204–205.
   PubMed Web of Science ®Google Scholar
• Carr, J.M. (1989) "Disseminated intravascular coagulation in cirrhosis", Hepatology 10, 103–110.
   PubMed Web of Science ®Google Scholar
• Mammen, E.F. (2000) "Coagulation defects in liver disease", Med. Clin. North Am. 78, 545–554.
   Google Scholar
• Paramo, J.A. and Rocha, E. (1993) "Hemostasis in advanced liver disease", Semin. Thromb. Hemost. 19, 184–190.
   PubMed Web of Science ®Google Scholar
• Joist, J.H. (1994) "Hemostatic abnormalities in liver disease", In: Colman, R.W., Hirsh, J., Marder, V.I. and Salzman, E.W., eds, Hemostasis and Thrombosis (Lippincott, Philadelphia), pp 906–920.
   Google Scholar
• Rapaport, S.I. (2000) "Coagulation problems in liver disease", Blood Coagul. Fibrinolysis 11\(Suppl. 1), S69—S74.
   PubMedGoogle Scholar
• Ejlersen, E., Melsen, T., Ingerslev, J., Andreasen, R.B. and Vilstrup, A. (2001) "Recombinant activated factor VII (rFVlia) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices", Scand. J. Gastroenterol. 36, 1081–1085.
   PubMed Web of Science ®Google Scholar
• Lodge, P., Jonas, S. and Jaeck, D. (2002) "Recombinant factor Vila (NovoSeven®) in partial hepatectomy: a randomized, placebo-controlled, double-blind clinical trial", American Association for the Study of Liver Diseases Annual Meeting, Boston, MA, Nov. 2002 ( Abstr. 177).
   Google Scholar
• Hendriks, H.G., Meijer, K., de Wolf, J.T., Porte, R.J., Klompmaker, I.J., Lip, H., Slooff, M.J. and Van der Meer, J. (2002) "Effects of recombinant activated factor VII on coagulation measured by thrombelastography in liver transplantation", Blood Coagul. Fibrinolysis 13, 309–313.
   PubMed Web of Science ®Google Scholar
• Gralnick, H.R. (1982) "Massive transfusion", In: Colman, R.W., Hirsh, J. and Marder, V.J., eds, Hemostasis and Thrombosis: Basic Principles and Clinical Practice (Lippincott, Philadelphia), pp 612–622.
   Google Scholar
• Blombäck, B., Carlsson, K., Fatah, K., Hessel, B. and Procyk, R. (1994) "Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation", Thromb. Res. 75, 521–538.
   PubMed Web of Science ®Google Scholar
• Grounds, M. (2003) "Recombinant factor Villa (rFVlia) and its use in severe bleeding in surgery and trauma: a review", Blood Rev. 17, S11—S21.
   PubMed Web of Science ®Google Scholar
• Friederich, P.W., Henny, CE, Messelink, E.J., Geerdink, M.G., Keller, T., Kurth, K.H., Buller, H.R. and Levi, M. (2003) "Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial", Lancet 362, 201–205.
   Google Scholar
• Aggarwal, A., Catlett, J. and Alcorn, K. (2001) "Use of recombinant activated factor VII (rFVlia) in the management of intractable bleeding in surgical and trauma patients", Blood 98, 66b, (Abstr.).
   Web of Science ®Google Scholar
• Svartholm, E., Annerhagen, V. and Lanne, T. (2002) "Treatment of bleeding in severe necrotizing pancreatitis with recombinant factor Vila", Anesthesiology 96, 1528.
   PubMed Web of Science ®Google Scholar
• Ng, H.J., Koh, L.P. and Lee, L.H. (2003) "Successful control of postsurgical bleeding by recombinant factor Vila in a renal failure patient given low molecular weight heparin and aspirin", Ann. Hematol. 82, 257–258.
   PubMed Web of Science ®Google Scholar
• White, B., McHale, J., Ravi, N., Reynolds, J., Stephen, R., Moriarty, J. and Smith, O.P. (1999) "Successful use of recombinant FVlia (NovoSeven®) in management of intractable post-surgical intraabdominal haemorrhage", Br. J. Haematol. 107, 677–678.
   PubMed Web of Science ®Google Scholar
• Laffan, M.A. and Cummins, M. (2000) "Recombinant factor Vila for intractable surgical bleeding", Blood 96, 85b (Abstr. 4048).
   Web of Science ®Google Scholar
• Vlot, A.J., Ton, E., Mackaay, A.J., Kramer, M.H. and Gaillard, C.A. (2000) "Treatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant factor VII", Am. J. Med. 108, 421–422.
   PubMed Web of Science ®Google Scholar
• Moscardo, F., Perez, F., De La Rubia, J., Balerdi, B., Lorenzo, J.I., Senent, M.L., Aznar, I., Carceller, S. and Sanz, M.A. (2001) "Successful treatment of severe intraabdominal bleeding associated with disseminated intravascular coagu-lation using recombinant activated factor VII", Br. J. Haematol. 113, 174–176.
   Google Scholar
• Hendriks, H.G., van der Maaten, J.M., de Wolf, J., Waterbolk, T.W., Slooff, M.J. and van der Meer, J. (2001) "An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII", Anesth. Analg. 93, 287–289.
   PubMed Web of Science ®Google Scholar
• Aldouri, M. (2002) "The use of recombinant factor Vila in controlling surgical bleeding in non-haemophiliac patients", Pathophysiol. Haemost. Thromb. 32\(Suppl. 1), 41–46.
   PubMedGoogle Scholar
• Zietkiewicz, M., Garlicki, M., Domagala, J., Wierzbicki, K., Drwila, R., Pfitzner, R. and Dziatkowiak, A. (2002) "Successful use of activated recombinant factor VII to control bleeding abnormalities in a patient with a left ventricular assist device", J. Thorac. Cardiovasc. Surg. 123, 384–385.
   PubMed Web of Science ®Google Scholar
• Potapov, E.V., Pasic, M., Bauer, M. and Hetzer, R. (2002) "Activated recombinant factor VII for control of diffuse bleeding after implantation of ventricular assist device", Ann. Thorac. Surg. 74, 2182–2183.
   PubMed Web of Science ®Google Scholar
• Von Heymann, C., Hotz, H., Konertz, W., Kox, W.J. and Spies, C. (2002) "Successful treatment of refractory bleeding with recombinant factor VIla after redo coronary artery bypass graft surgery", J. Cardiothorac. Vasc. Anesth. 94, 615–616.
   Google Scholar